MaxCyte to Participate in Upcoming November 2022 Investor Conferences

2022-11-02

细胞疗法

ROCKVILLE, Md., Nov. 02, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Company management will participate in the following investor conferences: Stifel Healthcare Conference Wednesday, November 16th at 3:00 p.m. Eastern Time Stephens Annual Investment Conference Thursday, November 17th at 10:00 a.m. Eastern Time Live and archived webcasts of the events will be available on the “Events” section of the MaxCyte investor relations website at . About MaxCyte MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® technology, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. MaxCyte Contacts: US IR Adviser Gilmartin Group David Deuchler, CFA +1 415-937-5400 jr@maxcyte.com US Media Relations Seismic Collaborative, A Spectrum Science Company Valerie Enes +1 408-497-8568 valerie@teamseismic.com Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden +44 (0)20 7886 2500 UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott / Chris Welsh +44 (0)203 709 5700 maxcyte@consilium-comms.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构